Slideshows Images Quizzes

Copyright © 2018 by RxList Inc. RxList does not provide medical advice, diagnosis or treatment. See additional information.

Prograf

Last reviewed on RxList: 6/22/2018
Prograf Side Effects Center

Last reviewed on RxList 6/22/2018

Prograf (tacrolimus) is an immunosuppressant used together with other medicines to prevent your body from rejecting a heart, liver, or kidney transplant. Some forms of Prograf are available in generic form. Common side effects of Prograf include:

  • shaking,
  • headache,
  • diarrhea,
  • constipation,
  • nausea,
  • vomiting,
  • upset stomach,
  • stomach pain,
  • loss of appetite,
  • trouble sleeping (insomnia), or
  • tingling or swelling of the hands or feet.

Tell your doctor if you experience serious side effects of Prograf including:

  • mental/mood changes,
  • dizziness,
  • change in the amount of urine,
  • tiredness,
  • pounding heartbeat,
  • hearing problems (such as hearing loss, ringing in the ears),
  • pain/redness/swelling of arms or legs,
  • easy bruising/bleeding,
  • muscle pain/cramps/weakness,
  • yellowing skin or eyes,
  • dark urine,
  • persistent nausea or vomiting, and
  • severe stomach or abdominal pain.

Dosing of Prograf is individualized based on clinical assessments of rejection and tolerability. Prograf may interact with chemotherapy, medicines to treat bowel disorder, antiviral medications, pain or arthritis medicines, antibiotics, other medications to prevent organ transplant rejection, birth control pills or hormone replacement, metoclopramide, mycophenolate, mofetil, sirolimus, St John's wort, lansoprazole, omeprazole, rifampin, rifabutin, potassium supplements, diuretics (water pills), calcium channel blockers, antifungals, HIV medicines, antacids containing magnesium or aluminum, or seizure medicine. Many other medicines interact with Prograf. Tell your doctor all prescription and over-the-counter medications and supplements you use. During pregnancy, Prograf should be used only when prescribed. This drug passes into breast milk and the effect on a nursing infant is unknown. Consult your doctor before breastfeeding.

Our Prograf (tacrolimus) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Prograf Consumer Information

Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

You may get infections more easily, even serious or fatal infections. Stop taking tacrolimus and call your doctor right away if you have signs of infection such as: sudden weakness or ill feeling, fever, chills, sweating, sore throat, painful mouth sores, skin warmth or redness, flu symptoms, muscle aches, cough, pale skin, easy bruising, or unusual bleeding.

Also call your doctor at once if you have:

  • general ill feeling, pain or swelling near your transplanted organ;
  • confusion, change in mental status, vision loss, seizure (convulsions);
  • little or no urination, swelling in your feet or ankles;
  • fast or pounding heartbeats, fluttering in your chest, shortness of breath, and sudden dizziness (like you might pass out);
  • high blood pressure--severe headache, pounding in your neck or ears;
  • high blood sugar--increased thirst, increased urination, hunger, fruity breath odor, nausea, loss of appetite, drowsiness, confusion;
  • high potassium level--nausea, weakness, tingly feeling, chest pain, irregular heartbeats, loss of movement;
  • low magnesium or phosphate--bone pain, jerky muscle movements, muscle weakness or limp feeling, slow reflexes;
  • low red blood cells (anemia)--pale skin, unusual tiredness, feeling light-headed or short of breath, cold hands and feet; or
  • signs of stomach bleeding--bloody or tarry stools, coughing up blood or vomit that looks like coffee grounds.

Common side effects may include:

  • infections, anemia, weakness;
  • high blood sugar, low levels of phoshate, potassium, or magnesium;
  • tremors or shaking, numbness or tingling;
  • nausea, diarrhea, constipation, stomach pain;
  • headache, general pain;
  • sleep problems (insomnia); or
  • swelling in your hands or feet.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Read the entire detailed patient monograph for Prograf (Tacrolimus)

Prograf Professional Information

SIDE EFFECTS

The following serious and otherwise important adverse drug reactions are discussed in greater detail in other sections of labeling:

Clinical Studies Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In addition, the clinical trials were not designed to establish comparative differences across study arms with regards to the adverse reactions discussed below.

Kidney Transplantation

The incidence of adverse reactions was determined in three randomized kidney transplant trials. One of the trials used azathioprine (AZA) and corticosteroids and two of the trials used mycophenolate mofetil (MMF) and corticosteroids concomitantly for maintenance immunosuppression.

PROGRAF-based immunosuppression in conjunction with azathioprine and corticosteroids following kidney transplantation was assessed in a trial where 205 patients received PROGRAF-based immunosuppression and 207 patients received cyclosporine-based immunosuppression. The trial population had a mean age of 43 years (mean ± SD was 43 ± 13 years on PROGRAF and 44 ± 12 years on cyclosporine arm), the distribution was 61% male, and the composition was White (58%), African-American (25%), Hispanic (12%), and Other (5%). The 12-month post-transplant information from this trial is presented below.

The most common adverse reactions (≥ 30%) observed in PROGRAF-treated kidney transplant patients are: infection, tremor, hypertension, abnormal renal function, constipation, diarrhea, headache, abdominal pain, insomnia, nausea, hypomagnesemia, urinary tract infection, hypophosphatemia, peripheral edema, asthenia, pain, hyperlipidemia, hyperkalemia, and anemia. Based on reported adverse reactions terms related to decreased renal function, nephrotoxicity was reported in approximately 52% of kidney transplantation patients.

Adverse reactions that occurred in ≥ 15% of kidney transplant patients treated with PROGRAF in conjunction with azathioprine are presented below:

Table 4. Kidney Transplantation: Adverse Reactions Occurring in ≥ 15% of Patients Treated with PROGRAF in Conjunction with Azathioprine (AZA)

  PROGRAF/AZA
(N = 205)
Cyclosporine/AZA
(N = 207)
Nervous System
  Tremor 54% 34%
  Headache 44% 38%
  Insomnia 32% 30%
  Paresthesia 23% 16%
  Dizziness 19% 16%
Gastrointestinal
  Diarrhea 44% 41%
  Nausea 38% 36%
  Constipation 35% 43%
  Vomiting 29% 23%
  Dyspepsia 28% 20%
Cardiovascular
  Hypertension 50% 52%
  Chest Pain 19% 13%
Urogenital
  Creatinine Increased 45% 42%
  Urinary Tract Infection 34% 35%
Metabolic and Nutritional
  Hypophosphatemia 49% 53%
  Hypomagnesemia 34% 17%
  Hyperlipemia 31% 38%
  Hyperkalemia 31% 32%
  Diabetes Mellitus 24% 9%
  Hypokalemia 22% 25%
  Hyperglycemia 22% 16%
  Edema 18% 19%
Hemic and Lymphatic
  Anemia 30% 24%
  Leukopenia 15% 17%
Miscellaneous
  Infection 45% 49%
  Peripheral Edema 36% 48%
  Asthenia 34% 30%
  Abdominal Pain 33% 31%
  Pain 32% 30%
  Fever 29% 29%
  Back Pain 24% 20%
Respiratory System
  Dyspnea 22% 18%
  Cough Increased 18% 15%
Musculoskeletal
  Arthralgia 25% 24%
Skin
  Rash 17% 12%
  Pruritus 15% 7%

Two trials were conducted for PROGRAF-based immunosuppression in conjunction with MMF and corticosteroids. In the non-US trial (Study 1), the incidence of adverse reactions was based on 1195 kidney transplant patients that received PROGRAF (Group C, n = 403), or one of two cyclosporine (CsA) regimens (Group A, n = 384 and Group B, n = 408) in combination with MMF and corticosteroids; all patients, except those in one of the two cyclosporine groups, also received induction with daclizumab. The trial population had a mean age of 46 years (range 17 to 76), the distribution was 65% male, and the composition was 93% Caucasian. The 12-month post-transplant information from this trial is presented below.

Adverse reactions that occurred in ≥ 10% of kidney transplant patients treated with PROGRAF in conjunction with MMF in Study 1 [Note: This trial was conducted entirely outside of the United States. Such trials often report a lower incidence of adverse reactions in comparison to U.S. trials] are presented below:

Table 5. Kidney Transplantation: Adverse Reactions Occurring in ≥ 10% of Patients Treated with PROGRAF in Conjunction with MMF (Study 1)

  PROGRAF (Group C) Cyclosporine (Group A) Cyclosporine (Group B)
(N = 403) (N = 384) (N = 408)
Diarrhea 25% 16% 13%
Urinary Tract Infection 24% 28% 24%
Anemia 17% 19% 17%
Hypertension 13% 14% 12%
Leukopenia 13% 10% 10%
Edema Peripheral 11% 12% 13%
Hyperlipidemia 10% 15% 13%
Key: Group A = CsA/MMF/CS, B = CsA/MMF/CS/Daclizumab,
C = Tac/MMF/CS/Daclizumab CsA = Cyclosporine, CS = Corticosteroids, Tac = Tacrolimus, MMF = mycophenolate mofetil

In the U.S. trial (Study 2) with PROGRAF-based immunosuppression in conjunction with MMF and corticosteroids, 424 kidney transplant patients received PROGRAF (n = 212) or cyclosporine (n = 212) in combination with MMF 1 gram twice daily, basiliximab induction, and corticosteroids. The trial population had a mean age of 48 years (range 17 to 77), the distribution was 63% male, and the composition was White (74%), African-American (20%), Asian (3%), and Other (3%). The 12-month post-transplant information from this trial is presented below.

Adverse reactions that occurred in ≥ 15% of kidney transplant patients treated with PROGRAF in conjunction with MMF in Study 2 are presented below:

Table 6. Kidney Transplantation: Adverse Reactions Occurring in ≥ 15% of Patients Treated with PROGRAF in Conjunction with MMF (Study 2)

  PROGRAF/MMF
(N = 212)
Cyclosporine/MMF
(N = 212)
Gastrointestinal Disorders
  Diarrhea 44% 26%
  Nausea 39% 47%
  Constipation 36% 41%
  Vomiting 26% 25%
  Dyspepsia 18% 15%
Injury, Poisoning, and Procedural Complications
  Post-Procedural Pain 29% 27%
  Incision Site Complication 28% 23%
  Graft Dysfunction 24% 18%
Metabolism and Nutrition Disorders
  Hypomagnesemia 28% 22%
  Hypophosphatemia 28% 21%
  Hyperkalemia 26% 19%
  Hyperglycemia 21% 15%
  Hyperlipidemia 18% 25%
  Hypokalemia 16% 18%
Nervous System Disorders
  Tremor 34% 20%
  Headache 24% 25%
Blood and Lymphatic System Disorders
  Anemia 30% 28%
  Leukopenia 16% 12%
Miscellaneous
  Edema Peripheral 35% 46%
  Hypertension 32% 35%
  Insomnia 30% 21%
  Urinary Tract Infection 26% 22%
  Blood Creatinine Increased 23% 23%

Less frequently observed adverse reactions in kidney transplantation patients are described under the subsection “Less Frequently Reported Adverse Reactions (> 3% and < 15%) in Liver, Kidney, and Heart Transplant Studies.”

Liver Transplantation

There were two randomized comparative liver transplant trials. In the U.S. trial, 263 adult and pediatric patients received tacrolimus and steroids and 266 patients received cyclosporine-based immunosuppressive regimen (CsA/AZA). The trial population had a mean age of 44 years (range 0.4 to 70), the distribution was 52% male, and the composition was White (78%), African-American (5%), Asian (2%), Hispanic (13%), and Other (2%). In the European trial, 270 patients received tacrolimus and steroids and 275 patients received CsA/AZA. The trial population had a mean age of 46 years (range 15 to 68), the distribution was 59% male, and the composition was White (95.4%), Black (1%), Asian (2%), and Other (2%).

The proportion of patients reporting more than one adverse event was > 99% in both the tacrolimus group and the CsA/AZA group. Precautions must be taken when comparing the incidence of adverse reactions in the U.S. trial to that in the European trial. The 12-month post-transplant information from the U.S. trial and from the European trial is presented below. The two trials also included different patient populations and patients were treated with immunosuppressive regimens of differing intensities. Adverse reactions reported in ≥ 15% in tacrolimus patients (combined trial results) are presented below for the two controlled trials in liver transplantation.

The most common adverse reactions (≥ 40%) observed in PROGRAF-treated liver transplant patients are: tremor, headache, diarrhea, hypertension, nausea, abnormal renal function, abdominal pain, insomnia, paresthesia, anemia, pain, fever, asthenia, hyperkalemia, hypomagnesemia, and hyperglycemia. These all occur with oral and IV administration of PROGRAF and some may respond to a reduction in dosing (e.g., tremor, headache, paresthesia, hypertension). Diarrhea was sometimes associated with other gastrointestinal complaints such as nausea and vomiting. Based on reported adverse reactions terms related to decreased renal function, nephrotoxicity was reported in approximately 40% and 36% of liver transplantation patients receiving PROGRAF in the U.S. and European randomized trials.

Table 7. Liver Transplantation: Adverse Reactions Occurring in ≥ 15% of Patients Treated with PROGRAF

  U.S. TRIAL EUROPEAN TRIAL
PROGRAF
(N = 250)
Cyclosporine/ AZA
(N = 250)
PROGRAF
(N = 264)
Cyclosporine/ AZA
(N = 265)
Nervous System
  Headache 64% 60% 37% 26%
  Insomnia 64% 68% 32% 23%
  Tremor 56% 46% 48% 32%
  Paresthesia 40% 30% 17% 17%
Gastrointestinal
  Diarrhea 72% 47% 37% 27%
  Nausea 46% 37% 32% 27%
  LFT Abnormal 36% 30% 6% 5%
  Anorexia 34% 24% 7% 5%
  Vomiting 27% 15% 14% 11%
  Constipation 24% 27% 23% 21%
Cardiovascular
  Hypertension 47% 56% 38% 43%
Urogenital
  Kidney Function Abnormal 40% 27% 36% 23%
  Creatinine Increased 39% 25% 24% 19%
  BUN Increased 30% 22% 12% 9%
  Oliguria 18% 15% 19% 12%
  Urinary Tract Infection 16% 18% 21% 19%
Metabolic and Nutritional
  Hypomagnesemia 48% 45% 16% 9%
  Hyperglycemia 47% 38% 33% 22%
  Hyperkalemia 45% 26% 13% 9%
  Hypokalemia 29% 34% 13% 16%
Hemic and Lymphatic
  Anemia 47% 38% 5% 1%
  Leukocytosis 32% 26% 8% 8%
  Thrombocytopenia 24% 20% 14% 19%
Miscellaneous
  Pain 63% 57% 24% 22%
  Abdominal Pain 59% 54% 29% 22%
  Asthenia 52% 48% 11% 7%
  Fever 48% 56% 19% 22%
  Back Pain 30% 29% 17% 17%
  Ascites 27% 22% 7% 8%
  Peripheral Edema 26% 26% 12% 14%
Respiratory System
  Pleural Effusion 30% 32% 36% 35%
  Dyspnea 29% 23% 5% 4%
  Atelectasis 28% 30% 5% 4%
Skin and Appendages
  Pruritus 36% 20% 15% 7%
  Rash 24% 19% 10% 4%

Table 8. Pediatric Liver Transplantation: Adverse Reactions Occurring in > 10% of Patients Treated with PROGRAF Granules (STUDY 01-13)

  PROGRAF Granules
(N = 91)
Cyclosporine
(N = 90)
Body as a Whole
  Fever 46% 51%
  Infection 25% 29%
  Sepsis 22% 20%
  CMV Infection 15% 24%
  EBV Infection 26% 11%
  Ascites 17% 20%
  Peritonitis 12% 7%
Cardiovascular System
  Hypertension 39% 47%
Digestive System
  Liver Function Tests Abnormal 37% 28%
  Diarrhea 26% 26%
  Vomiting 15% 13%
  Gastrointestinal Hemorrhage 11% 12%
  Bile Duct Disorder 12% 8%
  Gastroenteritis 12% 4%
Hemic and Lymphatic System
  Anemia 29% 19%
Metabolic and Nutritional Disorders
  Hypomagnesemia 40% 29%
  Acidosis 26% 17%
  Hyperkalemia 12% 10%
Respiratory System
  Pleural Effusion 22% 19%
  Bronchitis 11% 8%
Urogenital System
  Kidney Function Abnormal 13% 14%

Less frequently observed adverse reactions in liver transplantation patients are described under the subsection “Less Frequently Reported Adverse Reactions (> 3% and < 15%) in Liver, Kidney, and Heart Transplant Studies.”

Heart Transplantation

The incidence of adverse reactions was determined based on two trials in primary orthotopic heart transplantation. In a trial conducted in Europe, 314 patients received a regimen of antibody induction, corticosteroids, and azathioprine (AZA) in combination with PROGRAF (n = 157) or cyclosporine (n = 157) for 18 months. The trial population had a mean age of 51 years (range 18 to 65), the distribution was 82% male, and the composition was White (96%), Black (3%), and other (1%).

The most common adverse reactions (≥ 15%) observed in PROGRAF-treated heart transplant patients are: abnormal renal function, hypertension, diabetes mellitus, CMV infection, tremor, hyperglycemia, leukopenia, infection, anemia, bronchitis, pericardial effusion, urinary tract infection, and hyperlipemia. Based on reported adverse reactions terms related to decreased renal function, nephrotoxicity was reported in approximately 59% of heart transplantation patients in the European trial.

Adverse reactions in heart transplant patients in the European trial are presented below:

Table 9. Heart Transplantation: Adverse Reactions Occurring in ≥ 15% of Patients Treated with PROGRAF in Conjunction with Azathioprine (AZA)

  PROGRAF/AZA
(n = 157)
Cyclosporine/AZA
(n = 157)
Cardiovascular System
  Hypertension 62% 69%
  Pericardial Effusion 15% 14%
Body as a Whole
  CMV Infection 32% 30%
  Infection 24% 21%
Metabolic and Nutritional Disorders
  Diabetes Mellitus 26% 16%
  Hyperglycemia 23% 17%
  Hyperlipemia 18% 27%
Hemic and Lymphatic System
  Anemia 50% 36%
  Leukopenia 48% 39%
Urogenital System
  Kidney Function Abnormal 56% 57%
  Urinary Tract Infection 16% 12%
Respiratory System
  Bronchitis 17% 18%
Nervous System
  Tremor 15% 6%

In the European trial, the cyclosporine trough concentrations were above the pre-defined target range (i.e., 100 to 200 ng/mL) at Day 122 and beyond in 32% to 68% of the patients in the cyclosporine treatment arm, whereas the tacrolimus trough concentrations were within the pre-defined target range (i.e., 5 to 15 ng/mL) in 74% to 86% of the patients in the tacrolimus treatment arm.

In a U.S. trial, the incidence of adverse reactions was based on 331 heart transplant patients that received corticosteroids and PROGRAF in combination with sirolimus (n=109), PROGRAF in combination with MMF (n=107) or cyclosporine modified in combination with MMF (n=115) for 1 year. The trial population had a mean age of 53 years (range 18 to 75), the distribution was 78% male, and the composition was White (83%), African-American (13%) and other (4%).

Only selected targeted treatment-emergent adverse reactions were collected in the U.S. heart transplantation trial. Those reactions that were reported at a rate of 15% or greater in patients treated with PROGRAF and MMF include the following: any target adverse reactions (99%), hypertension (89%), hyperglycemia requiring antihyperglycemic therapy (70%), hypertriglyceridemia (65%), anemia (hemoglobin < 10.0 g/dL) (65%), fasting blood glucose > 140 mg/dL (on two separate occasions) (61%), hypercholesterolemia (57%), hyperlipidemia (34%), WBCs < 3000 cells/mcL (34%), serious bacterial infections (30%), magnesium < 1.2 mEq/L (24%), platelet count < 75,000 cells/mcL (19%), and other opportunistic infections (15%).

Other targeted treatment-emergent adverse reactions in PROGRAF-treated patients occurred at a rate of less than 15%, and include the following: Cushingoid features, impaired wound healing, hyperkalemia, Candida infection, and CMV infection/syndrome. Other less frequently observed adverse reactions in heart transplantation patients are described under the subsection “Less Frequently Reported Adverse Reactions (> 3% and < 15%) in Liver, Kidney and Heart Transplant Studies.”

New Onset Diabetes After Transplant

Kidney Transplantation

New Onset Diabetes After Transplant (NODAT) is defined as a composite of fasting plasma glucose ≥ 126 mg/dL, HbA1C ≥ 6%, insulin use ≥ 30 days, or oral hypoglycemic use. In a trial in kidney transplant patients (Study 2), NODAT was observed in 75% in the PROGRAF-treated and 61% in the NEORAL-treated patients without pre-transplant history of diabetes mellitus (Table 10) [see Clinical Studies].

Table 10. Incidence of New Onset Diabetes After Transplant at 1 year in Kidney Transplant Recipients in a Phase 3 Trial (Study 2)

Parameter Treatment Group
PROGRAF/MMF
(n = 212)
NEORAL/MMF
(n = 212)
NODAT 112/150 (75%) 93/152 (61%)
  Fasting Plasma Glucose ≥ 126 mg/dL 96/150 (64%) 80/152 (53%)
  HbA1C ≥ 6% 59/150 (39%) 28/152 (18%)
  Insulin Use ≥ 30 days 9/150 (6%) 4/152 (3%)
  Oral Hypoglycemic Use 15/150 (10%) 5/152 (3%)

In early trials of PROGRAF, Post-Transplant Diabetes Mellitus (PTDM) was evaluated with a more limited criterion of “use of insulin for 30 or more consecutive days with < 5-day gap” in patients without a prior history of insulin-dependent diabetes mellitus or non-insulin dependent diabetes mellitus. Data are presented in Tables 11 to 14. PTDM was reported in 20% of PROGRAF/Azathioprine (AZA)-treated kidney transplant patients without pre-transplant history of diabetes mellitus in a Phase 3 trial (Table 11). The median time to onset of PTDM was 68 days. Insulin dependence was reversible in 15% of these PTDM patients at one year and in 50% at 2 years post-transplant. African-American and Hispanic kidney transplant patients were at an increased risk of development of PTDM (Table 12).

Table 11. Incidence of Post-Transplant Diabetes Mellitus and Insulin Use at 2 Years in Kidney Transplant Recipients in a Phase 3 Trial using Azathioprine (AZA)

Status of PTDM* PROGRAF/AZA CsA/AZA
  Patients without pre-transplant history of diabetes mellitus 151 151
  New onset PTDM*, 1st Year 30/151 (20%) 6/151 (4%)
  Still insulin-dependent at one year in those without prior history of diabetes 25/151 (17%) 5/151 (3%)
  New onset PTDM* post 1 year 1 0
  Patients with PTDM* at 2 years 16/151 (11%) 5/151 (3%)
*Use of insulin for 30 or more consecutive days, with < 5 day gap, without a prior history of insulin-dependent diabetes mellitus or non-insulin dependent diabetes mellitus.

Table 12. Development of Post-Transplant Diabetes Mellitus by Race or Ethnicity and by Treatment Group During First Year Post Kidney Transplantation in a Phase 3 Trial

Patient Race Patients Who Developed PTDM*
PROGRAF Cyclosporine
African-American 15/41 (37%) 3 (8%)
Hispanic 5/17 (29%) 1 (6%)
Caucasian 10/82 (12%) 1 (1%)
Other 0/11 (0%) 1 (10%)
Total 30/ 151 (20%) 6 ( 4%)
*Use of insulin for 30 or more consecutive days, with < 5-day gap, without a prior history of insulin-dependent diabetes mellitus or non-insulin dependent diabetes mellitus.

Liver Transplantation

Insulin-dependent PTDM was reported in 18% and 11% of PROGRAF-treated liver transplant patients and was reversible in 45% and 31% of these patients at 1 year post-transplant, in the U.S. and European randomized trials, respectively (Table 13). Hyperglycemia was associated with the use of PROGRAF in 47% and 33% of liver transplant recipients in the U.S. and European randomized trials, respectively, and may require treatment [see Clinical Studies Experience].

Table 13. Incidence of Post-Transplant Diabetes Mellitus and Insulin Use at 1 Year in Liver Transplant Recipients

Status of PTDM* US Trial European Trial
PROGRAF Cyclosporine PROGRAF Cyclosporine
Patients at risk 239 236 239 249
New Onset PTDM* 42 (18%) 30 (13%) 26 (11%) 12 (5%)
Patients still on insulin at 1 year 23 (10%) 19 (8%) 18 (8%) 6 (2%)
*Use of insulin for 30 or more consecutive days, with < 5 day gap, without a prior history of insulin-dependent diabetes mellitus or non-insulin dependent diabetes mellitus.
Patients without pre-transplant history of diabetes mellitus.

Heart Transplantation

Insulin-dependent PTDM was reported in 13% and 22% of PROGRAF-treated heart transplant patients receiving mycophenolate mofetil (MMF) or azathioprine (AZA) and was reversible in 30% and 17% of these patients at one year post-transplant, in the U.S. and European randomized trials, respectively (Table 14). Hyperglycemia defined as two fasting plasma glucose levels ≥126 mg/dL was reported with the use of PROGRAF plus MMF or AZA in 32% and 35% of heart transplant recipients in the U.S. and European randomized trials, respectively, and may require treatment [see Clinical Studies Experience].

Table 14. Incidence of Post-Transplant Diabetes Mellitus and Insulin Use at 1 Year in Heart Transplant Recipients

Status of PTDM* US Trial European Trial
PROGRAF/ MMF Cyclosporine/ MMF PROGRAF/ AZA Cyclosporine/ AZA
Patients at risk 75 83 132 138
New Onset PTDM* 10 (13%) 6 (7%) 29 (22%) 5 (4%)
Patients still on insulin at 1 year 7 (9%) 1 (1%) 24 (18%) 4 (3%)
*Use of insulin for 30 or more consecutive days without a prior history of insulin-dependent diabetes mellitus or non-insulin dependent diabetes mellitus.
Patients without pre-transplant history of diabetes mellitus.
7-12 months for the U.S. trial.

Less Frequently Reported Adverse Reactions (> 3% And < 15%) In Liver, Kidney, And Heart Transplant Studies

The following adverse reactions were reported in either liver, kidney, and/or heart transplant recipients who were treated with tacrolimus in clinical trials.

  • Nervous System [see WARNINGS AND PRECAUTIONS]: Abnormal dreams, agitation, amnesia, anxiety, confusion, convulsion, crying, depression, elevated mood, emotional lability, encephalopathy, hemorrhagic stroke, hallucinations, hypertonia, incoordination, monoparesis, myoclonus, nerve compression, nervousness, neuralgia, neuropathy, paralysis flaccid, psychomotor skills impaired, psychosis, quadriparesis, somnolence, thinking abnormal, vertigo, writing impaired
  • Special Senses: Abnormal vision, amblyopia, ear pain, otitis media, tinnitus
  • Gastrointestinal: Cholangitis, cholestatic jaundice, duodenitis, dysphagia, esophagitis, flatulence, gastritis, gastroesophagitis, gastrointestinal hemorrhage, GGT increase, GI disorder, GI perforation, hepatitis, hepatitis granulomatous, ileus, increased appetite, jaundice, liver damage, esophagitis ulcerative, oral moniliasis, pancreatic pseudocyst, stomatitis
  • Cardiovascular: Abnormal ECG, angina pectoris, arrhythmia, atrial fibrillation, atrial flutter, bradycardia, cardiac fibrillation, cardiopulmonary failure, congestive heart failure, deep thrombophlebitis, echocardiogram abnormal, electrocardiogram QRS complex abnormal, electrocardiogram ST segment abnormal, heart failure, heart rate decreased, hemorrhage, hypotension, phlebitis, postural hypotension, syncope, tachycardia, thrombosis, vasodilatation
  • Urogenital: Acute kidney failure [see WARNINGS AND PRECAUTIONS], albuminuria, BK nephropathy, bladder spasm, cystitis, dysuria, hematuria, hydronephrosis, kidney failure, kidney tubular necrosis, nocturia, pyuria, toxic nephropathy, urge incontinence, urinary frequency, urinary incontinence, urinary retention, vaginitis
  • Metabolic/Nutritional: Acidosis, alkaline phosphatase increased, alkalosis, ALT (SGPT) increased, AST (SGOT) increased, bicarbonate decreased, bilirubinemia, dehydration, GGT increased, gout, healing abnormal, hypercalcemia, hypercholesterolemia, hyperphosphatemia, hyperuricemia, hypervolemia, hypocalcemia, hypoglycemia, hyponatremia, hypoproteinemia, lactic dehydrogenase increase, weight gain
  • Endocrine: Cushing’s syndrome
  • Hemic/Lymphatic: Coagulation disorder, ecchymosis, hematocrit increased, hypochromic anemia, leukocytosis, polycythemia, prothrombin decreased, serum iron decreased
  • Miscellaneous: Abdomen enlarged, abscess, accidental injury, allergic reaction, cellulitis, chills, fall, flu syndrome, generalized edema, hernia, mobility decreased, peritonitis, photosensitivity reaction, sepsis, temperature intolerance, ulcer
  • Musculoskeletal: Arthralgia, cramps, generalized spasm, leg cramps, myalgia, myasthenia, osteoporosis
  • Respiratory: Asthma, emphysema, hiccups, lung function decreased, pharyngitis, pneumonia, pneumothorax, pulmonary edema, rhinitis, sinusitis, voice alteration
  • Skin: Acne, alopecia, exfoliative dermatitis, fungal dermatitis, herpes simplex, herpes zoster, hirsutism, neoplasm skin benign, skin discoloration, skin ulcer, sweating

Postmarketing Adverse Reactions

The following adverse reactions have been reported from worldwide marketing experience with tacrolimus. Because these reactions are reported voluntarily from a population of uncertain size it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Decisions to include these reactions in labeling are typically based on one or more of the following factors: (1) seriousness of the reaction, (2) frequency of the reporting, or (3) strength of causal connection to the drug.

Other Reactions Include
  • Cardiovascular: Atrial fibrillation, atrial flutter, cardiac arrhythmia, cardiac arrest, electrocardiogram T wave abnormal, flushing, myocardial infarction, myocardial ischemia, pericardial effusion, QT prolongation, Torsade de Pointes, venous thrombosis deep limb, ventricular extrasystoles, ventricular fibrillation, myocardial hypertrophy [see WARNINGS AND PRECAUTIONS]
  • Gastrointestinal: Bile duct stenosis, colitis, enterocolitis, gastroenteritis, gastroesophageal reflux disease, hepatic cytolysis, hepatic necrosis, hepatotoxicity, impaired gastric emptying, liver fatty, mouth ulceration, pancreatitis hemorrhagic, pancreatitis necrotizing, stomach ulcer, veno-occlusive liver disease
  • Hemic/Lymphatic: Agranulocytosis, disseminated intravascular coagulation, hemolytic anemia, neutropenia, pancytopenia, thrombocytopenic purpura, thrombotic thrombocytopenic purpura, pure red cell aplasia [see WARNINGS AND PRECAUTIONS]
  • Infections: Cases of progressive multifocal leukoencephalopathy (PML), sometimes fatal; polyoma virus-associated nephropathy, (PVAN) including graft loss [see WARNINGS AND PRECAUTIONS]
  • Metabolic/Nutritional: Glycosuria, increased amylase including pancreatitis, weight decreased
  • Miscellaneous: Feeling hot and cold, feeling jittery, hot flushes, multi-organ failure, primary graft dysfunction
  • Nervous System: Carpal tunnel syndrome, cerebral infarction, hemiparesis, leukoencephalopathy, mental disorder, mutism, posterior reversible encephalopathy syndrome (PRES) [see WARNINGS AND PRECAUTIONS], progressive multifocal leukoencephalopathy (PML) [see WARNINGS AND PRECAUTIONS], quadriplegia, speech disorder, syncope
  • Respiratory: Acute respiratory distress syndrome, interstitial lung disease, lung infiltration, respiratory distress, respiratory failure
  • Skin: Stevens-Johnson syndrome, toxic epidermal necrolysis
  • Special Senses: Blindness, blindness cortical, hearing loss including deafness, photophobia
  • Urogenital: Acute renal failure, cystitis hemorrhagic, hemolytic-uremic syndrome

Read the entire FDA prescribing information for Prograf (Tacrolimus)

Related Resources for Prograf

Read the Prograf User Reviews »

© Prograf Patient Information is supplied by Cerner Multum, Inc. and Prograf Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Health Solutions From Our Sponsors

CONTINUE SCROLLING FOR RELATED ARTICLE